What happened
On August 27, 2026, the FDA approved Lisraya (brepocitinib) tablets for the treatment of dermatomyositis in adults, granting Priovant Therapeutics Inc. the first FDA-approved oral treatment option for this rare autoimmune disease. The agency said Lisraya is a once-daily oral Janus kinase and TYK2 inhibitor. The approval was supported by a phase 3 randomized, double-blind, multicenter, placebo-controlled study, NCT05437263, in 241 adults with dermatomyositis.
Patients were randomized to brepocitinib 30 mg once daily, brepocitinib 15 mg once daily, or placebo over 52 weeks. According to the FDA, patients treated with Lisraya 30 mg had a higher average Total Improvement Score at week 52 than placebo, along with improvements in physical function and skin disease activity. They were also more likely to reduce corticosteroid use by week 48. Common adverse reactions included upper respiratory tract infection, headache, fatigue, urinary tract infection, and nausea. Discontinuation due to adverse reactions occurred in 6% of participants treated with Lisraya 30 mg versus 11% with placebo. The drug carries a boxed warning for serious infections, increased all-cause mortality, malignancies, major adverse cardiovascular events, and thrombosis. FDA also granted Orphan Drug and Priority Review designations.
Why it matters
The immediate significance is straightforward: FDA has now put an on-label oral option into a disease area the agency itself described as marked by limited treatment choices and reliance on therapies meant for other diseases. For prescribers and patients, the approval is not just mechanistic promise. It is anchored to a controlled phase 3 study with a 52-week treatment period and a standardized outcome measure spanning muscle strength, physical function, skin and other disease activity, muscle enzymes, and physician and patient assessments.
For rare-disease investors, the approval also gives Priovant a clearer commercial starting point in a space where differentiation may rest as much on route of administration and real-world tolerability as on efficacy alone. Detailed drug monographs are at ClinicalRx.ai.
The catch, and payers will focus on this quickly, is that Lisraya arrives with the boxed warning profile the FDA spelled out for serious infections, increased all-cause mortality, malignancies, major adverse cardiovascular events, and thrombosis. One likely read is that access discussions will center on how much value plans place on a first approved oral option versus the monitoring and risk-management expectations that come with a JAK and TYK2 inhibitor.
Investors should also watch whether Priovant can translate the corticosteroid-reduction signal and functional benefits cited by FDA into a compelling reimbursement story in 2026 and beyond. For employer-side PBM benchmarking, see RxPBM.ai.
